Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide with Lenvatinib and PD-1 in Advanced HCC
NCT07184424Completed
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- May 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenalidomide in hepatocellular carcinoma (HCC), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoints: Progression-Free Survival at 1 year and Overall Survival at 1 year. Started May 2023; status: completed.
02
Drugs
lenalidomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07184424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184424.